The Trump administration announced Friday that it would delay the implementation of Biden-era rules intended to limit coverage of unproven, costly bandages known as skin substitutes.
The policy will be It’s late until 2026 allowing businesses to take advantage of the loopholes in Medicare rules to continue to set higher prices for new products. The New York Times reported Thursday that businesses are selling these bandages to doctors at discounted prices, while doctors are charging Medicare for the price of full stickers and pocketing the differences.
According to an analysis conducted by Earty Read, an actuarial company that assesses the costs of large healthcare companies, Medicare spending has skyrocketed above $10 billion from $1.6 billion in 2024. Some experts said bandage spending is one of the biggest examples of waste in the history of Medicare, an insurance program for the elderly.
The Super PAC for President Trump’s election campaign received a $2 million donation from Extreme Care, a leading seller of skin alternatives. Trump has criticised his social media policy twice, saying it hurts patients who use the product with diabetic pain.
“‘Crooked Joe’ has broken through policies that will lead to more suffering and death for Medicare diabetics,” Trump wrote on Truth Social in March.
Extremity care also criticized the plan, claiming it would disrupt the supply chain, eliminate innovation and increase costs for both doctors and patients. The company says it complies with high ethical standards, but did not respond immediately to requests for comment regarding the new delay in the policy.
Over 120 skin alternatives are on the market. They average an average of $5,089 per square inch, with the most expensive time exceeding $23,000.
Biden-era rules would have limited Medicare coverage for a small subset of products that have been shown to be effective in randomized clinical trials. The new policy will be applied to patients using ulcer and leg pain bandages known as ulcers. This can be caused by diabetes or poor circulation.
Medicare said in a Friday’s Statement It will consider policies as part of the transition to a new administration. During that time, he said, “We believe it is important to maintain patient access to skin replacement products with quality evidence of effectiveness.”
Mass Coalition, a group supporting the skin substitute industry, said it was “satisfied” with the delay. Public relations officer Preya Nonona Pinto said the group is looking forward to working with Medicare on “coverage policies and payment reforms that guarantee access to skin replacements.”
Source: www.nytimes.com
